Actively Recruiting
Artificial Intelligence-based Screening Models for Prevention and Early Detection of Colorectal Cancer
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-29
1400
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Colorectal cancer screening is based on the fecal occult blood test (FIT), which has low sensitivity for adenomatous polyps, based on the currently used cut-off. Risk factors such as obesity, diabetes, alcohol, and cigarette smoking are associated with the presence of high-risk neoplasia in the screening population. CADe systems appear to increase ADR in screening programs; however, uncertainty remains regarding their true effectiveness. The study could provide the tools to: 1. devise a personalized pathway of CRC screening so as to refer to colonoscopy (with CAD or without CAD depending on the results that will be obtained) those at high risk of carrying neoplasms amenable to removal or curative treatment; 2. define risk categories for theoretical screening models giving the possibility of moving from the concept "one size fits all" to that of "personalized and precision prevention".
CONDITIONS
Official Title
Artificial Intelligence-based Screening Models for Prevention and Early Detection of Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects aged 50-69 years who underwent the fecal occult blood screening program
- Male and female sex
- Positive fecal occult blood test (FIT) with a cut-off of 20 micrograms HgB/g of stool
- Provided written consent to participate in the study
You will not qualify if you...
- Subjects who do not understand the Italian language
- Previous total colectomy or bowel resections
- Colonoscopy performed in the previous 12 months
- Contraindications to colonoscopy
- Contraindications to sedation or anesthesia
- Personal history of colorectal cancer
- Hereditary gastrointestinal cancer syndromes including familial adenomatous polyposis (FAP), attenuated FAP, MutYH-associated polyposis, Lynch or Lynch-like syndrome, and serrated polyposis syndrome
- Inflammatory bowel disease such as Crohn's disease or ulcerative colitis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy, 40138
Actively Recruiting
Research Team
G
Giovanni Barbara, MD
CONTACT
C
Chiara Pierantoni, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here